CD274 and neoplasm: The strategies include determining the optimal PD-L1 dose to balance immune stimulation and suppression, localizing PD-L1 expression to the desired tissue and reducing PD-L1 levels in the liver and other tumor-prone organs using tissue-specific promoters or modified AAV capsids.